Together with other international research teams, researchers from SDCC have collected data on medical treatment for people with type 2 diabetes, and compared this with incidence of heart failure and mortality.
The epidemiological research team at SDCC has contributed Danish register data to a major international study of 1.3 million patients with type 2 diabetes.
The study shows that treating type 2 diabetes with SGLT-2 inhibitors is related to lower incidence of heart failure and death (see fact box).
“The Empa-Reg randomized study showed that treating patients with both diabetes and cardiovascular disease with the empagliflozin SGLT-2 inhibitor reduced the incidence of both heart failure and death from cardiovascular disease. Our study confirms findings of lower mortality and less incidence of heart failure in a large, unselected diabetes population under treatment with all types of SGLT-2 inhibitors. The positive findings are apparent, irrespective of whether or not patients have cardiovascular disease,” said Prof. Marit Eika Jørgensen, consultant and Head of Clinical Epidemiology.
The study includes register information from Denmark, Norway, Sweden, Germany, the United Kingdom and the US. Danish data is from the Landspatientregistret (the national patient registry), the register of reasons for death and the Lægemiddelregistret (national medicines registry).
At Steno, we are extremely pleased that our long experience in register-based research could contribute to such an important international study using high-quality Danish data.
About SGLT-2 inhibitors
SGLT2 stands for Sodium Glucose Co Transporter, and it is a protein that increases excretion of sugar through urine. This means that the concentration of glucose in the blood stream drops, giving a drop in HbA1c, weight loss and a drop in systolic blood pressure.